Navigation Links
High prevalence of NSAID prescription in those at risk of heart attack/death in primary care
Date:6/14/2013

Madrid, Spain, 14 June 2013: New study data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate a high prevalence of NSAID prescriptions in patients at risk of ischaemic heart disease (IHD).

Published evidence suggest significant cardiovascular implications of NSAIDs for patients, with an immediate mortality risk demonstrated in patients who had suffered a myocardial infarction (MI, heart attack) even when prescribed treatment duration was less than one week.2

NSAIDs are used to relieve pain and signs of inflammation, such as fever, swelling and redness. Although they can be taken temporarily to provide short-term relief, they are commonly prescribed for the chronic treatment of rheumatic patients in primary care.

Dr Carl Orr, Department of Medicine, Royal College of Surgeons, Dublin, Ireland commented, "The side effect profile and safety of NSAIDs has been commonly reported, but little is known about treatment duration and its implications for cardiovascular risk. These data demonstrate an immediate increase in the risk of death and MI, challenging the safety of even short term use. The introduction of physician guidelines to assist safe prescribing of this class of drug is vital, and the only way to keep patient safety at the forefront of disease management."

Software was used to analyse 10,000 patients registered with a large primary care facility; patients over 50 years, who had been prescribed NSAIDs for any duration, and had documented IHD, diabetes mellitus and/or hypertension were identified. Over a two month period in late 2012, 108 patients were prescribed NSAIDs; 36% had established ischaemic heart disease or risk factors for cardiovascular disease. Mean duration of treatment was 265 days, 56% were prescribed NSAIDs for longer than one month, and 15% for a year or longer. In 56% of cases diclofenac was the NSAID prescribed.

"We find it disconcerting that diclofenac was prescribed in 56% of cases and suggest that recommendations to switch to safer alternatives are a critical component of any physician guidelines," concluded Dr Orr.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Tree nut consumption associated with lower body weight and lower prevalence of health risks
2. IADR/AADR published study estimates high prevalence of periodontis in US adults
3. Controlling vascular disease may be key to reducing prevalence of Alzheimers disease
4. Diabetic patients have higher prevalence of hearing impairment
5. CDC and NIH survey provides first report of state-level COPD prevalence
6. USC, Oxford researchers find high fructose corn syrup-global prevalence of diabetes link
7. Autopsy-based study examines prevalence of atherosclerosis among US service members
8. High prevalence of drug-resistant MRSA found in nursing homes
9. Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment, compares benefit of surveillance and surgery for management of small kidney tumors
10. Fibromyalgia prevalence at 2.1 percent of general German population
11. Newly incarcerated have 1 percent acute hepatitis C prevalence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: